NRF2 can transcriptionally activate SLC7A11, whereas ARF (also known as CDKN2A) negatively regulates NRF2's activity in a p53-independent manner, indicating that NRF2 is a major target of p53-independent tumor suppression by ARF [36]. The gene discussed is CDKN2A; the disease is neoplasm.